Biogen Surges as MS Pill Meets Study Goals

October 2011
MondayMorning;10/31/2011, Vol. 19 Issue 39, p1
The article discusses a comparative study on the sales of two multiple sclerosis oral drugs namely BG-12 from Biogen Idec Inc. and Copaxone from Teva Pharmaceutical Industries Ltd. It mentions the popularity gained by BG-12 after the second phase of clinical trials and states that the drug reduces the risk of the disease by 51 percent in comparison with 29 percent by Copaxone. It further informs that after the third phase of clinical trial of BG-12, it will become a front line drug.


Related Articles

  • The Majority of Surveyed U.S. Neurologists Selected Tysabri as the Most Effective Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis, When Compared to Other Currently Available Agents.  // Biomedical Market Newsletter;5/7/2011, p88 

    The declares the drug, Tysabri from Biogen Idec Inc./Elan Pharma International Ltd.'s Tysabri, as the most effective therapy for the treatment of relapsing-remitting multiple sclerosis (MS). The overwhelming response among surveyed neurologists in the U.S., considering Tysabri, been consistent...

  • Recent Multiple Sclerosis Market Events Have Resulted in Treatment Algorithm Modifications According to a Recent BioTrends Chart Audit Report.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p747 

    The article reports on the annual patient audit of BioTrends Research Group LLC which aims to compare the self-report of neurologists to what happens at the patient in the U.S. in 2011. Neurologists distinguish the opportunity for Teva Pharmaceutical Industries Ltd.'s laquinimod and Biogen Idec...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;May2008, Vol. 7 Issue 5, p6 

    The article offers news briefs related to the treatment of multiple sclerosis (MS) in the U.S. Teva Pharmaceutical Industries reports the positive results of the study evaluating relapsing and remitting MS patients. MediciNova Inc. reports on the completion of the clinical trial of MN-166, a...

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p15 

    The article reports on the positive result of the test of laquinimod, an oral disease modifying treatment for multiple sclerosis. Phase III clinical trials are initiated by Teva and Swedish biotech partner Active Biotech AB. It is stated that laquinimod is expected to become the fifth oral...

  • Study shows benefit of switch to Teva's Copaxone in treatment of multiple sclerosis.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p12 

    Focuses on the clinical study of Copaxone, a treatment regimen for multiple sclerosis developed by Teva Pharmaceutical Industries Ltd. Presentation of the clinical study of Copaxone; Efficacy of Copaxone to treat multiple sclerosis; Indications for the drug.

  • Teva announces encouraging data from Phase III multiple sclerosis study.  // PharmaWatch: CNS;Nov2012, Vol. 11 Issue 11, p10 

    The article reports on the results of the Phase III glatiramer acetate low-frequency administration (GALA) study on the dosing regimen of glatiramer acetate (GA), a therapeutic agent. GA is contained in COPAXONE or glatiramer acetate injection, which is used to treat relapsing-remitting multiple...

  • Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p121 

    The article reports on the presentation of data from a study conducted by Teva Pharmaceutical Industries Ltd. and Active Biotech AB on the potential of laquinod in treating multiple sclerosis. The findings of the phase III study suggests the effectiveness of laquinimod in reducing annualized...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Feb2011, Vol. 10 Issue 2, p4 

    The article provides updates on the development of drugs for multiple sclerosis. A complete response letter from the U.S. Food and Drug Administration (FDA) has been received by Teva Pharmaceutical Industries Ltd. for its supplemental New Drug Application (sNDA). Applications to update Tysabri...

  • MS drug help.  // Drug Topics;2/6/95, Vol. 139 Issue 3, p20 

    Reports that the Pharmaceutical Marketing Alliance of Ronkonkoma, N.Y. will offer insurance guidance and information to multiple sclerosis patients receiving copolymer-1. Development of co-polymer 1 by Teva Pharmaceuticals; Contact number of Teva for more information.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics